Evaluating the Pharmacokinetics and Safety of Miricorilant

← catalyst calendar

NCT07553663 · readout in 72 d

Sponsored by Corcept Therapeutics (industry) · CORT — their whole pipeline →.

Phase

Phase 1

Status

Recruiting

Study type

Interventional

Design

Na · None · Treatment

Enrollment

15estimated

Sites

Country

United States

Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →

Source: ClinicalTrials.gov, retrieved 2026-08-19

Dates

each axis at the precision it was filed, with the registry's own basis

Date

Filed

Basis

What it is

Start

2026-04-30

actual

When the study began enrolling

Primary completion

2026-10-30

estimated

The date the last participant is measured for the primary outcome — the readout window

Study completion

2026-10-30

estimated

The whole study's end, after follow-up

First posted

2026-04-28

actual

When this record first appeared on the registry

Results posted

—

When the sponsor posted results to the registry

Record updated

2026-05-26

actual

The sponsor's own last edit to this record — every projection above is as current as this date

What it studies

Conditions

Nonalcoholic Steatohepatitis (NASH)
Metabolic Dysfunction-Associated Steatohepatitis (MASH) / Nonalcoholic Steatohepatitis (NASH) With Compensated Cirrhosis
Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD)
Non-alcoholic Fatty Liver Disease (NAFLD)